• This launch makes Kenya the first country in East Africa to operationalize this biannual prevention tool, reinforcing the nation’s commitment to ending the HIV epidemic.

On February 26, 2026, Kenya officially entered a new era of public health as Cabinet Secretary (CS) for Health Aden Duale launched Lenacapavir, a long‑acting injectable for HIV pre‑exposure prophylaxis (PrEP).

The landmark ceremony at Riruta Health Centre in Nairobi marked the first phase of a national rollout designed to deliver innovative, people‑centered prevention solutions.

The event drew high‑ranking health officials, including Principal Secretary for Medical Services Dr. Ouma Oluga, National AIDS & STI Control Programme (NASCOP) Chief Executive Officer (CEO) Dr. Andrew Mulwa, Director of Family Health Dr. Issak Bashir, Dagoretti North Member of Parliament (MP) Beatrice Elachi, and representatives from key partners such as Dr. Jacqueline Kitulu (Global Fund), Dr. Richard Amenyah (UNAIDS).

Others include Dr. Neema Kimambo (WHO), Jennifer Galbraith (USG), and Mary Nyaguthi (AHF).

This launch makes Kenya the first country in East Africa to operationalize this biannual prevention tool, reinforcing the nation’s commitment to ending the HIV epidemic.

Read More

  1. Why Wealth Isn’t Evil: Lessons from 'Rich Dad Poor Dad'
  2. Parliament Moves to Strengthen Kenya’s Nuclear Energy Programme
  3. Kenya Positions Itself as Africa’s Investment Hub Ahead of Capital Week 2026

The rollout followed the arrival of an initial shipment of 21,000 starter doses on February 17, 2026. This consignment, delivered in partnership with the Global Fund, was received by Dr. Patrick Amoth alongside US Embassy representative Brian Rettman.

The significance of this biomedical breakthrough extends beyond medical efficacy to its impact on health equity. For the first time, African nations are accessing cutting‑edge medicine simultaneously with wealthier countries, closing a long‑standing gap in global health access.

Through collaborative negotiations, Kenya secured Lenacapavir at $40 per person annually. This affordability is a cornerstone of the country’s Universal Health Coverage agenda, ensuring that life‑saving technology reaches those who need it most.

By offering Lenacapavir alongside existing tools such as daily oral PrEP and the dapivirine vaginal ring, Kenya is building a comprehensive arsenal to protect vulnerable populations, including adolescent girls, young women, and discordant couples.

This proactive step not only safeguards individual health but also positions Kenya as a regional leader in the sustainable, science‑driven fight against HIV.

Stay connected with us on WhatsApp and Facebook for instant updates and breaking news as it happens.